Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flu Vaccine Schedule Expansion Could Cost Public Sector $60 Mil. Annually

Executive Summary

Expanding influenza vaccination recommendations to include infants between six and 23 months and children who are household contacts of high-risk groups could increase costs to the public sector by $59.6 mil. annually

You may also be interested in...



Pediatric flu vaccine data

Influenza strain data and vaccine response research for pediatric populations "has not really gotten the priority...it deserves" due to limited resources, Office of Vaccines Research & Review Supervisory Medical Officer Roland Levandowski, MD, tells agency's vaccines advisory committee. In January 2002, committee "strongly recommended" that strain surveillance data be obtained from a pediatric population to study immunogenicity and efficacy of the vaccine. At Feb. 20 meeting on strain selection, several committee members cited a pressing need for pediatric data in light of recommendations for increased flu vaccine use in children (1"The Pink Sheet" July 8, 2002, p. 12)...

Pediatric flu vaccine data

Influenza strain data and vaccine response research for pediatric populations "has not really gotten the priority...it deserves" due to limited resources, Office of Vaccines Research & Review Supervisory Medical Officer Roland Levandowski, MD, tells agency's vaccines advisory committee. In January 2002, committee "strongly recommended" that strain surveillance data be obtained from a pediatric population to study immunogenicity and efficacy of the vaccine. At Feb. 20 meeting on strain selection, several committee members cited a pressing need for pediatric data in light of recommendations for increased flu vaccine use in children (1"The Pink Sheet" July 8, 2002, p. 12)...

Aventis Fluzone pediatric

Aventis Fluzone preservative-free influenza vaccine clears FDA for infants ages six to 35 months Sept. 4. Limited quantity of vaccine will be available for shipment in early to mid-November; larger quantities could be available should the Advisory Committee on Immunization Practices "expand its position on pediatric influenza immunization," Aventis says (1"The Pink Sheet" July 8, p. 12)...

Related Content

UsernamePublicRestriction

Register

PS040117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel